Oncology Central

miRNAs in medullary thyroid carcinoma: when will they be relevant to the clinic?


Despite a better knowledge in the molecular signaling pathways involved in the pathogenesis of medullary thyroid carcinoma (MTC), this disease, when metastatic at diagnosis, shows an unfavorable prognostic outcome [1,2]. Recent clinical trials using specific targeted therapies have shown promising results, but the low rates of partial or complete responses and the short duration of responses in these types of patients, has prompted researchers to investigate for novel biological mechanisms of the disease and to take into account to develop alternative targeted therapies [2,3].

To view restricted content, please:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.